Further states Maraviroc a CCR5 antagonist...a Pfizer product was generally safe in treatment-experienced patients (938) whereas only 46 in total died. It was stated "Rates of deaths were low during follow-up".
On the Maraviroc (MVC) expanded access Program (EAP) [abstract H-209] ...one of the authors was our very own... Dr. J. Lalezari....and Yes...our stock sits at $.2099...very carefully controlled.